The constitutive activation of the RAS–ERK pathway as a result of KRAS mutations has led to the development of MEK inhibitors (MEKi) as a potential therapeutic strategy for the treatment of KRAS-mutant cancers [35]. The gene discussed is MAP2K7; the disease is cancer.